Regorafenib HCl, the hydrochloric acid salt of regorafenib (also known as BAY 73-4506), is a potent inhibitor of multi-kinase including VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 values of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively.

Regorafenib (also known as BAY 73-4506; BAY-73-4506) is a potent and orally bioavailable multi-kinase inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 values of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively.

TG101209 is a novel, potent, orally bioactive and selective small molecule JAK2 inhibitor with IC50 of 6 nM.

Regorafenib monohydrate (also known as BAY 73-4506 monohydrate), the hydrated form of Regorafenib, is an orally bioavailable multi-kinase inhibitor targeting kinases such as VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 values of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively.